Brought to you by:
The future of vascular surgery (and the role a hybrid OR plays in it)
This advertorial is sponsored by Siemens. Two leaders in vascular surgery preview the future of interventional imaging and consider the emergence of the hybrid operating room (OR) as a future model for success. The hybrid OR is emerging as a…
One-year SAVVE trial results are ‘most encouraging data ever produced for a bioprosthetic vein valve’
The one-year data from the SAVVE trial represent the “most encouraging clinical data that have ever been produced for a bioprosthetic deep vein valve” in more than half a century of attempts at developing such a device, according to one…
Positive one-year data for new venous valve portends promising future in chronic venous insufficiency treatment
SAVVE trial principal investigators discuss results showing 98.4% VenoValve device patency, 85% clinically meaningful benefit and an 80% rate of ulcer size reduction at 12 months. Fresh from delivering positive one-year data from the Surgical Antireflux Venous Valve Endoprosthesis (SAVVE)…
Novel bioabsorbable perivascular wrap aims to reduce AVF failure
Ellen Dillavou, MD, division chief of vascular surgery at WakeMed Heart Center in Raleigh, North Carolina, primary investigator (PI) for the VenoStent trial, presented new data during the 2024 VEITHsymposium in New York City (Nov. 19–23) about the SelfWrap (VenoStent)…
When RCTs are essential for novel vascular access device regulation
As part of a 2024 VEITHsymposium (New York City; Nov. 19–23) debate, Robert E Lee, MD, a medical officer recently retired from the Food and Drug Administration (FDA), presented an argument in favor of when the use of randomized controlled…
Venous VQI celebrates decade milestone
At the recent VEITHsymposium (Nov. 19–23) in New York City, Marc Passman, MD, reflected on the achievements of the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) venous arm, in collaboration with the American Venous Forum (AVF), since its…
In search of the ‘holy grail’: New analysis brings aneurysm rupture prediction closer
A rupture prediction-based algorithm is set to enhance patient selection for abdominal aortic aneurysm (AAA) repair. This is according to Randy Moore, MD, a vascular surgeon at the University of Calgary in Calgary, Canada, who, at the 2024 VEITHsymposium (Nov.…
WAVE trial AVG cohort also benefits at six months with Wrapsody
Newly released six-month results from single-arm arteriovenous graft (AVG) cohort in the WAVE (Wrapsody arteriovenous access efficacy) trial showed target lesion and access circuit primary patency rates of nearly 82% and 68.8%, respectively. The latest data on the Wrapsody cell-permeable…
One-year data from VenoValve US pivotal trial emerges
Envveno Medical has announced that it will present one-year data on all patients from the VenoValve US pivotal trial today at the VEITHsymposium (19–23 November, New York, USA). The definitive one-year data support the application submitted earlier this week by Envveno Medical seeking…
PMA application submitted for VenoValve device
enVVeno Medical today announced it has submitted an application with the U.S. Food and Drug Administration (FDA) seeking approval to market the VenoValve—a surgical venous valve implant for chronic venous insufficiency—in the USA. Definitive one year data from the application…